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Abstract 
 
Background: 
Recommendations of current clinical guidelines are informed by limited economic evidence. 
 
Aims: 
A formal economic evaluation of three modalities of psychotherapy for patients with cluster B 
personality disorders. 
 
Method: 
A probabilistic decision-analytic model to assess the cost-effectiveness of outpatient, day 
hospital, and inpatient psychotherapy over 5 years in terms of cost per recovered patient-
year and cost per quality-adjusted life year (QALY). Analyses were conducted from both 
societal and payer perspectives. 
 
Results: 
From the societal perspective, the most cost-effective choice switched from outpatient to day 
hospital psychotherapy at a threshold of €12,274 per recovered patient-year; and from day 
hospital to inpatient psychotherapy at €113,298. In terms of cost per QALY, the optimal 
strategy changed at €56,325 and €286,493 per QALY, respectively. From the payer 
perspective, the switch points were at €9,895 and €155,797 per recovered patient-year, and 
€43,427 and €561,188 per QALY. 
 
Conclusions: 
Outpatient psychotherapy and day hospital psychotherapy are the optimal treatments for 
patients with cluster B personality disorders in terms of cost per recovered patient-year and 
cost per QALY.  
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Introduction 
 
Cluster B personality disorders (PD), including borderline, antisocial, histrionic, and 
narcissistic PD, are among the most prevalent mental disorders in the general population1,2 
and mental healthcare settings.3,4 Moreover, these disorders are associated with high 
societal costs and a low quality of life.5,6 Although different in many respects, a common 
feature of cluster B PD is a rather dramatic and impulsive manifestation that is considered 
more persistent and resistant to change than cluster C PD (i.e., avoidant, dependent, and 
obsessive-compulsive PD) but less so than cluster A PD (i.e., paranoid, schizoid, and 
schizotypal PD). Currently, several treatments with demonstrated efficacy for borderline PD 
are being adapted and tested for antisocial PD, suggesting a partially common nature to 
these disorders.7 Additionally, contemporary classification models of PD increasingly focus 
on dimensions rather than categories, and cluster B PD seem to have similarly high scores 
on dimensions of behavioral and emotional disinhibition, and antagonism.8 This paradigm 
shift makes it clinically relevant to include the full range of cluster B PD in analyses rather 
than focus solely on the more common borderline PD.    
A multidisciplinary clinical guideline in the Netherlands recently identified various 
modalities of psychotherapy, including outpatient, day hospital, and inpatient psychotherapy, 
to be preferential for cluster B PD9, consistent with two other clinical guidelines that focused 
on borderline PD.10,11 While based on strong evidence of efficacy,12 the economic impact of 
these recommendations has not yet been explored, and few cost-effectiveness analyses of 
PD interventions exist that can guide decision making with respect to clinical practices and 
health care resource allocation. Recently, the Study on Cost-Effectiveness of Personality 
disorder Treatment (SCEPTRE) was conducted with the purpose of providing data for 
economic evaluations of various psychotherapeutic treatments for PD. Used in a decision-
analytic framework, the data on health benefits and resource use from this study can be 
synthesized to evaluate the relative performance of health interventions under conditions of 
uncertainty and imperfect data.13 The objective of this study was to assess the cost-
effectiveness of three modalities of psychotherapy in treating cluster B PD (i.e., outpatient 
psychotherapy, day hospital psychotherapy, and inpatient psychotherapy) and to inform 
decision makers about the value of these treatment options. We incorporated clinical and 
economic patient-level data from the SCEPTRE trial in a simulation model to compare the 
strategies over a five-year time horizon in terms of costs per recovered patient-year and 
costs per quality-adjusted life year (QALY).  
 
 
Methods 
 
Model 
We used a previously-developed Markov cohort model13,14 to simulate the transition of 
a cohort of patients with cluster B PD through mutually-exclusive and collectively exhaustive 
health states over time, based on data from the SCEPTRE trial. The model is then used to 
estimate the impact of different interventions on the patient population. The underlying 
clinical process driving the current model and by which the health states are defined is 
‘clinically significant change’, based on a statistical approach to defining meaningful change 
in psychotherapy research.15 To calculate the cut off points and the reliable change index 
required for this approach, norm scores based on the Symptom Checklist-90 Revised (SCL-
90-R) were used as treatment outcome measures for both the functional and the 
dysfunctional population.16 Patients are classified into one of four health states: (1) recovered 
(if the magnitude of change is statistically reliable and the patient ends up within normal limits 
on the variable of interest), (2) improved (if the patient shows statistically reliable change but 
ends therapy still somewhat dysfunctional), (3) unchanged (if the magnitude of change is not 
statistically reliable, the method cannot determine whether or not the change is clinically 
significant), and (4) relapsed or deteriorated (if a statistically reliable change is in the 
opposite direction to that indicative of improvement). At anytime, patients can also die from 
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suicide or age-specific background mortality. The structure of the Markov model is shown in 
Figure 1. 
Four types of parameters were used in the model: (1) transition probabilities, which 
govern the movement between the five states at each cycle, (2) treatment costs of the three 
modalities of psychotherapy, (3) costs of health care utilization and productivity losses 
incurred by patients in each state, and (4) health state utilities, which reflect the health-
related quality of life experienced by patients in each state. These data were obtained from a 
single patient-level data source (i.e., the SCEPTRE trial), a nonrandomized clinical trial. 
Strengths and limitations of the study design have been discussed elsewhere.17,18 To 
overcome the problem of selection bias, we controlled for initial differences in patient 
characteristics with the propensity score method (see below). The results are based on 
intention-to-treat analyses. 
Transitions between health states in the model was assumed to occur at a constant 
interval of every six months, corresponding to multiple changes in pathology, symptoms, 
treatment decisions, or costs for patients with PD.  
To be consistent with many other trial-based economic evaluations in the literature, 
we chose a five-year time horizon, which is two years beyond the duration of the clinical trial. 
With respect to the transition probabilities, we extrapolated for the last two years of the 
analysis and considered several methods of extrapolation. Based on the trends observed 
during the study, we elected to average the last two observations (i.e., years 2 and 3) from 
the trial and hold those values constant in years 4 and 5 of the analysis. For other model 
inputs, data collection did not stop at three years; indeed, we relied on questionnaires that 
were administered in the fourth year to estimate the costs and utilities associated with 
different health states and kept these values constant for the fifth year. We reported results 
as costs per recovered patient-year and costs per quality-adjusted life year (QALY) over the 
five years using the model; costs and QALYs were discounted at an annual rate of 4.0% and 
1.5% respectively, consistent with guidelines for economic evaluations in the Netherlands.19 
In a sensitivity analysis, we studied the impact of applying a 3% discount rate for both costs 
and health outcomes as recommended by UK and US economic guidelines. The base case 
analysis was conducted from the societal perspective, and a secondary analysis from the 
payer perspective. 
 
Recruitment and assignment 
Patients were recruited from a consecutive series of admissions to six mental health 
care institutes in the Netherlands offering specialized psychotherapy for adult patients with 
PD. Diagnoses were based on the Dutch version20 of the Structured Interview for DSM-IV 
Personality (SIDP-IV).21 For this particular analysis, inclusion criteria were a diagnosis of 
cluster B PD, age 18 to 70 years, assignment to a specified dosage of psychotherapeutic 
treatment for PD, and Dutch literacy. Exclusion criteria were psychotic disorders (e.g., 
schizophrenia), organic cerebral impairment, and mental retardation. Comorbid Axis I and 
Axis II disorders were allowed.  
From March 2003 to March 2006, 1379 individuals completed the intake procedure 
and were selected for various treatment options. Of those, 241 patients were eligible, 
provided informed consent, and entered the study (Table 1). Patients were assigned to one 
of three treatment groups, based on a comprehensive assessment battery combined with the 
expert opinion of clinicians:  outpatient, day hospital, and inpatient psychotherapy. In the 
outpatient strategy, patients are offered up to two sessions per week. In the day hospital 
strategy, patients are offered psychotherapy combined with sociotherapy and/or non-verbal 
therapies for 1-5 days per week. The inpatient strategy offers the same, but patients reside in 
the treatment centers 5-7 days per week. Mean (SD) duration of treatment for these three 
strategies was 15.1 (7.1), 10.4 (4.7), and 9.3 (2.9) months, respectively.  
 
Input data 
Transition probabilities – The proportion of patients in each of the health states was 
determined at 6, 12, 18, 24, 30, and 36 months after baseline from the SCEPTRE trial. 
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Based on the difference between the frequency distributions over time, the probabilities of 
transitioning from one state to another in each six-month time period were calculated. 
Transition probabilities among the recovered, improved, unchanged, and relapsed or 
deteriorated health states are available upon request.  
 
Costs – Costs were estimated from both societal and payer perspectives. The calculations 
from the societal perspective included direct medical costs (i.e., primary treatment costs and 
costs of health care utilization post-discharge) and direct non-medical costs (i.e., lost 
productivity due to time spent in treatment), as well as indirect costs (i.e., future lost 
productivity due to disease), while the payer perspective included only direct medical costs. 
Mean primary treatment costs for the three strategies were calculated by multiplying the 
resource quantities with the 2007 unit costs or prices of the corresponding treatment options. 
We obtained data from the hospital finance departments on staff salaries, equipment, 
buildings and departmental overheads, and used a micro-costing approach to derive the cost 
of a treatment session and an inpatient day. The resource quantities were collected from the 
hospital data systems. Costs due to productivity loss because of patients’ time in treatment 
were also estimated and included in the analysis from the societal perspective. For patients 
with paid employment at enrollment, mean costs were calculated by multiplying the actual 
days (inpatient psychotherapy, day hospital psychotherapy) and hours (outpatient 
psychotherapy) spent in treatment by the net income of the patient per day and per hour, 
respectively. The mean (SE) treatment costs were €7,445 (511) for outpatient 
psychotherapy, €23,279 (1,738) for day hospital psychotherapy, and €35,218 (1,354) for 
inpatient psychotherapy.  
Post-discharge costs due to health care utilization and productivity losses, likely to be 
substantial, were also included. The Trimbos and Institute for Medical Technology 
Assessment (iMTA) Questionnaire on Costs Associated with Psychiatric Illness (TiC-P) was 
used to collect data on direct medical and indirect costs.22 For direct medical costs, the total 
number of medical visits (e.g. outpatient visits, hospital lengths of stay, use of medication) 
was multiplied by the 2003 unit prices of the corresponding health care services.23,24 The 
reference unit prices of health care services for 2003 were adjusted to prices in 2007 using 
the consumer price index.25 The mean direct medical costs over the recall period of the TiC-P 
(i.e., four weeks) were multiplied by 6.5 to calculate the six-month costs to correspond to the 
model cycle length. For indirect costs, we obtained data on absence from work, reduced 
efficiency at work, and difficulties with job performance from the TiC-P short form of the 
Health and Labor Questionnaire.26 The days of short-term absence from work and actual 
hours missed at work because of health-related problems were multiplied by the net income 
of the patient per day and per hour, respectively. The number of lost working days per patient 
was calculated, taking into account the number of days and hours of paid employment of the 
patient per week. To value long-term absence from work, we applied the friction-cost 
method, which takes into account the fact that a formerly unemployed person may replace a 
person who becomes disabled.27 The period needed to replace a worker (the so-called 
friction period) is estimated to be five months; we therefore assumed the maximum indirect 
costs to society were limited to productivity losses during a period of five months. The cost 
estimates from the societal perspective used in the analysis are summarized in Table 2. For 
each strategy, the model calculates the expected cost by taking a weighted average of the 
costs of each health state and the proportion of the cohort in each health state at each six-
month period; the total expected cost of the strategy is then calculated by summing over the 
five year time horizon. 
 
Health utilities – To reflect the diminished quality of life of patients with PD, health utility 
weights were assigned to each health state, based on the EuroQol EQ-5D which records 
quality of life in five dimensions: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression.28 Each dimension is divided into three response levels: no problems, 
some or moderate problems, and extreme problems or complete inability. A total of 243 
different possible health states are each weighted to derive a single index score between 
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−0.33 (worst imaginable health state) and 1.00 (best imaginable health state). The Dutch 
norm scores were used for calculating the mean EQ-5D index values.29 The mean quality of 
life utilities of a year spent in each of the model health states for each cycle are summarized 
in Table 2. The expected number of QALYs for each strategy was estimated by weighing the 
duration of time in a particular health state by the utility of that health state and then summing 
over all health states in each cycle. The expected number of QALYs per patient over five 
years was calculated by summing over all cycles.   
 
Mortality rates – Patients in the recovered health state were assumed to face a risk of death 
equivalent to that observed in the general population. These age- and sex-specific mortality 
rates were obtained from standard life tables.30 Moreover, we assumed patients in the 
improved, unchanged and relapsed or deteriorated health states faced an elevated risk of 
death due to suicide, based on the SCEPTRE data. 
 
Propensity score method 
To overcome the problem of selection bias, we controlled for initial differences in 
patient characteristics with the multiple propensity score method.31 The estimated propensity 
score is defined as the conditional probability of assignment to a particular treatment, given a 
set of observed pre-treatment characteristics. Details of the method and the variables used 
to estimate the propensity scores are described elsewhere.32 Multinomial regression 
analyses were conducted to adjust the transition probabilities for the multiple propensity 
scores. 
 
Analysis 
In order to reflect uncertainty in our parameter values, we conducted a probabilistic 
analysis in which distributions were assigned to the input parameters of the model (i.e., 
gamma distributions for costs, beta distributions for utilities, and Dirichlet distributions for 
probability parameters).13 Multiple simulations were conducted in which a single value for 
each parameter was randomly sampled from the corresponding distribution, creating a 
unique parameter set. One thousand parameter sets were sampled and used in the model to 
calculate the expected costs, expected recovery rate, and QALY for each strategy.  
The mean values of costs, recovered patient-years, and QALYs across all 1000 
simulations were used to calculate incremental cost-effectiveness ratios (ICER) associated 
with each strategy, defined as the additional cost divided by the additional health benefit 
associated with one strategy as compared with the next-less-costly strategy. The most cost-
effective strategy was then identified by comparing the ICERs of different strategies against 
various threshold values, which reflect the decision maker’s willingness-to-pay (WTP) for an 
additional unit of effect. Strategies below a specific WTP value generally represent good 
value for money; the “most cost-effective” strategy is the strategy with the highest ICER 
below the WTP threshold, representing the option that yields the highest level of benefit for 
an acceptable cost.  
In order to report on the impact of the uncertainty in the parameter values, cost-
effectiveness acceptability curves (CEAC) were created to indicate the probability of each 
option being cost-effective conditional on the decision maker’s WTP for a recovered patient-
year or QALY.33 Finally, the cost-effectiveness acceptability frontier (CEAF) was plotted to 
portray each CEAC over the range of threshold values for which each option is estimated to 
be the most cost-effective, as well as the threshold ICER at which there are changes in the 
optimal modality (i.e., “switch points”).34  
 
 
Results 
 
Five-year costs and health outcomes 
The mean five-year costs and health outcomes from the societal perspective are 
presented in Table 3. The table shows that the mean costs are substantially lower for 
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outpatient psychotherapy, suggesting that the higher treatment costs of the day hospital and 
inpatient modalities are not offset by savings elsewhere, such as reductions in costs due to 
health care utilization and productivity losses. The rank ordering of strategies by effect is the 
same for both recovered patient-years and QALYs, indicating inpatient psychotherapy as the 
most effective option. With respect to the percentage of patients residing in the recovered 
health state at year five, day hospital psychotherapy is associated with the highest percent 
recovered. Outpatient psychotherapy appears to be consistently the least effective option.  
 
Cost-effectiveness analysis from the societal perspective 
The cost-effectiveness ratios for each strategy, reported as cost per recovered 
patient-year and cost per QALY over a five-year time horizon, are displayed in Table 4. 
Outpatient psychotherapy yields the lowest costs and health benefits; day hospital 
psychotherapy shows higher costs and effects and was associated with an ICER of €12,274 
per recovered patient-year and an ICER of €56,325 per QALY compared to outpatient 
psychotherapy. Inpatient psychotherapy yields the highest costs and health benefits and was 
associated with an ICER of €113,298 per recovered patient-year and an ICER of €286,493 
per QALY compared to day hospital psychotherapy.   
To display the impact of parameter uncertainty, we plotted the relationship between 
cost and health outcomes for each of the three competing psychotherapy modalities over 
1000 simulations in the cost-effectiveness plane (Figure 2). When plotting costs against 
recovered patient-years (panel A), we found substantial uncertainty about both costs and 
effects for all treatment options. When using QALYs as the health measure (panel B), we 
found equal uncertainty about costs, whereas the uncertainty in effect was less substantial. 
The observed differences among the three treatment modalities relating to the effects were 
more pronounced in terms of recovered patient-years than QALYs. 
Figure 3 shows the cost-effectiveness acceptability curves (CEAC), which indicate 
the probability of each strategy being cost-effective at different values of the societal 
willingness-to-pay (WTP) for a unit of health benefit. In terms of cost per recovered patient-
year, outpatient psychotherapy has the highest probability of being cost-effective for values 
of the societal WTP below €12,500. For values between €12,500 and €103,100 per 
recovered patient-year, day hospital psychotherapy is likely to be the most cost-effective. For 
values above €103,100 per recovered patient-year, inpatient psychotherapy has the highest 
probability of being cost-effective. In terms of costs per QALY, the same pattern of results 
can be observed, but the switch points were located at threshold values of €59,700 and 
€298,000, respectively. By definition, the CEAC crosses the Y-axis at the probability that the 
intervention under evaluation is cost-saving, as a WTP of zero implies that only cost 
determines cost-effectiveness (formula: WTP*∆effect – ∆costs > 0). 35 According to the 
current analysis, outpatient psychotherapy has a probability of being cost-saving in 
approximately 84 percent of model simulations; in contrast, day hospital and inpatient 
psychotherapy have a negligible probability of being cost-saving. 
While it is helpful to know the impact of uncertainty on results, the probability of a 
strategy being cost-effective is not sufficient to determine the optimal option. Decisions 
should be made on the basis of expected net benefit, regardless of the uncertainty 
associated with the decision.33 To identify the optimal treatment option (i.e., the option with 
the highest expected net benefit for a given cost), the cost-effectiveness acceptability 
frontiers (CEAF) were plotted (Figure 4). The CEAF of cost per recovered patient-year 
shows the range of threshold values over which outpatient psychotherapy (€0 to €12,274), 
day hospital psychotherapy (€12,274 to € 113,298), and inpatient psychotherapy (above 
€113,298) have the highest expected net benefit and can be considered the optimal choice. 
The switch points, at which there is a change in the optimal option, correspond to the ICERs 
between outpatient and day hospital psychotherapy, and day hospital and inpatient 
psychotherapy. In terms of cost per QALY, the switch points were located at threshold values 
of €56,325 and €286,493, respectively. If society’s WTP for a QALY is below the threshold 
value of €56,325 outpatient psychotherapy is the most cost-effective choice; above this value 
(and below €286,493), the optimal strategy would be day hospital psychotherapy. When we 
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varied the discount rate to 3% per year for both costs and health outcomes, the optimal 
option changed from outpatient psychotherapy to day hospital psychotherapy and from day 
hospital psychotherapy to inpatient psychotherapy at threshold values of €12,120 and 
€132,866 per recovered patient-year, and €58,035 and €283,755 per QALY, respectively. 
 
Cost-effectiveness analysis from the payer perspective 
The CEAF of cost per recovered patient-year and cost per QALY from the payer 
perspective show the same pattern of results as from the societal perspective. However, the 
switch points were located at different threshold values: €9,895 and €155,797 per recovered 
patient-year, and €43,427 and €561,188 per QALY. When using a discount rate of 3% per 
year on outcomes, the switch points shifted marginally to threshold values of €9,495 and 
€204,278 per recovered patient-year, and €44,580 and €500,151 per QALY. 
 
 
Discussion  
 
Using decision-analytic modeling, we estimated the cost-effectiveness of three 
modalities of psychotherapy for cluster B PD over a five-year time horizon from both societal 
and payer perspectives. To our knowledge, this is the first assessment of the cost-
effectiveness of treatment modalities for this population based on a formal decision-analytic 
modeling approach. As recommendations of current clinical guidelines in the Netherlands 
have been informed by limited economic evidence, we believe this study has the potential to 
inform clinical decision-making and health care resource allocations.   
Our findings indicate that when the societal WTP does not exceed €12,274 per 
recovered patient-year, outpatient psychotherapy provides the highest expected net benefit. 
If society is willing to pay more than €12,274 per recovered patient-year, day hospital 
psychotherapy is the optimal choice. Notably, inpatient psychotherapy would not be 
considered the most cost-effective treatment modality unless the threshold value reached 
€113,298. Defining an acceptable threshold for a recovered patient-year is challenging, and 
without a common health metric, the cost-effectiveness ratios cannot be readily compared 
with interventions for other illnesses; for example, the costs of a cluster B PD recovered 
patient-year can only be compared to a depression recovered patient-year if they experience 
the same burden of disease. The use of QALYs as the health outcome allows for such a 
comparison across disease burdens, although there is no universally-accepted threshold 
value. Our results in terms of cost per QALY can be interpreted according to 
recommendations by the Dutch council for Public Health and Health care.36 For acutely life-
threatening illnesses (with a maximum burden of disease), an explicit maximum of €80,000 
per QALY was recommended. For less life-threatening illnesses that only affect quality of life, 
the council recommends a proportional lower acceptable threshold. Cluster B PD are 
associated with a severe impairment in quality of life.6 The observed burden of 0.49 (i.e., 
mean EQ-5D index value of 0.51; range, 0.50 to 0.52) indicates that treatments may cost up 
to €39,200 per QALY to be acceptable. Based on this threshold value, outpatient 
psychotherapy can be identified as the most cost-effective and thus optimal option as it 
provides the greatest benefit below the threshold.  
The adoption decision for outpatient psychotherapy is robust over the discount rates 
applied, which could be expected because we only model outcomes over a five-year time 
horizon. 
Our results suggest that the two cost-effectiveness measures with different health 
outcomes yield similar trends in results, with outpatient psychotherapy being the optimal 
intervention at low levels of the societal WTP, day hospital psychotherapy at higher levels, 
and inpatient psychotherapy at the highest levels. The switch points in terms of cost per 
QALY occurs at higher threshold values, which can be explained by the fact that the 
distinction between modalities regarding health benefits was more pronounced in terms of 
recovery rate than in terms of QALYs. Consequently, the relatively low costs of outpatient 
psychotherapy carries more weight in the calculations of cost per QALY than of cost per 
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recovered patient-year and leads to more favorable results for outpatient psychotherapy. 
Previous studies have suggested that the EQ-5D may be insensitive in capturing changes in 
the quality of life of patients with borderline PD.37,38 However, the health state utility weights 
calculated and used in the current analysis indicate that the EQ-5D, used to generate 
QALYs, can be considered sensitive to changes in patients with cluster B PD. For example, 
patients in the recovered health state show health utility weights (i.e., a quality of life) 
approaching the utility weight observed in the normal (nonclinical) population (0.85); patients 
in the unchanged health state have a relatively stable utility weight compared to their value at 
enrollment (0.51); and patients in the relapsed or deteriorated health state were assigned 
much lower health utilities compared to enrollment. Despite the sensitivity of the EQ-5D in 
distinguishing quality of life associated with particular health states, QALYs are nonetheless 
less adequate measures for discriminating levels of change between the different modalities 
of psychotherapy. 
The cost-effectiveness results for the two effect measures indicate that outpatient 
psychotherapy and day hospital psychotherapy are more cost-effective for cluster B PD than 
inpatient psychotherapy. Our findings are consistent with the scarce existing economic 
evidence identified by Brazier and colleagues in their systematic review evaluating the cost-
effectiveness of psychological interventions for borderline PD.38 Based on best available 
evidence, their review suggests that both outpatient and day hospital treatment (i.e., 
dialectical behavioral therapy and mentalization based therapy) are likely to be a cost-
effective treatment modality for borderline PD.     
Several clinical implications can be derived from our analyses. From a health-
economic perspective, outpatient psychotherapy and day hospital psychotherapy should be 
considered the options of first choice for patients with cluster B PD, based on accepted WTP 
thresholds. Interestingly, this conclusion is consistent with several efficacy and effectiveness 
studies.12 Note however, that this study attempts to inform recommendations from the public 
health (i.e., population) perspective and should be not used for individual decision-making. 
Although we used primary patient-level data from a clinical study, we used those data to 
inform population averages (and plausible ranges) for our parameters. As a result, we were 
limited in our ability to examine individual-level heterogeneity such that there will undoubtedly 
be some patients for whom inpatient psychotherapy may be the best option. Also, we have to 
emphasize that cost-effectiveness is only one aspect of medical decision-making, so in daily 
clinical practice other important factors that were not considered in our model must be 
considered, such as individual preferences, past history, insufficient or even pathogenic 
social support systems. Our study has identified inpatient psychotherapy as an effective but 
expensive option; future research should test patient-treatment matching hypotheses in this 
respect.   
The major strength of this study was the collective use of the state of the art 
methodology and patient-level primary data to evaluate the cost-effectiveness of health care 
interventions. Decision-analytic modeling provides a framework for informed decision making 
under conditions of uncertainty. Specifically, it allows for exploration of the impact of 
uncertainty across multiple parameters simultaneously, and projection of results beyond the 
time horizon of the clinical trial. Furthermore, the availability of primary data from such a 
large patient trial provided a unique opportunity to inform the parameters of our model, as 
most modeling studies are based on secondary data. Data from future studies can be used 
to update the parameters of this existing probabilistic cost-effectiveness model. 
Assumptions were made in this model-based analysis. To correspond to the model 
cycle length, the costs of health care utilization post-discharge were multiplied by 6.5 to 
estimate the half-yearly costs. The extrapolation of these costs is based on the assumption 
that the recall period of four weeks of the TiC-P is representative for half a year. This 
assumption was tested in the same population in a previously published study, indicating that 
on a population level there was no significant difference between the costs as measured with 
a recall period of a year compared to a recall period of four weeks.5 We therefore believe that 
the costs calculated in the present study are a reasonable estimation of the actual costs 
generated over the model cycle length of six months. 
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Our analysis has several limitations. First, the model is developed using data from a 
treatment-seeking patient population, and in particular for those who seek specialized 
psychotherapy for personality problems. Therefore, the applicability of the results to non-
treatment seekers, forensic care, or patients who admit with a primary Axis I diagnosis, is 
limited. Second, despite the fact that this population is known to use criminal justice 
resources, these costs were not included in the analysis, which leads to an underestimation 
of the true societal costs. Third, this study compares only three modalities of psychotherapy, 
whereas the included treatments may also differ in terms of other characteristics such as 
theoretical orientation and therapeutic techniques. This limitation is somewhat mitigated by 
studies showing that theoretical orientation as a treatment parameter might only account for 
minor differences in effects – if any,39,40 and is not likely to be associated with costs. This is 
however not true for duration as a treatment parameter; future research should therefore 
address optimal dosing in terms of treatment duration. Finally, our analyses were based on a 
clinical trial with a nonrandomized study design. That patients were not randomized over 
treatment conditions, however, is not a drawback but rather an advantage within the context 
of economic evaluations, because nonrandomized studies are likely to be more 
representative and thus externally valid with respect to costs and effects.17,18 Moreover, 
randomization between existing treatment options is no longer feasible, because once 
information about a therapy’s clinical effectiveness is available, patients may not be willing to 
participate in experiments simply to evaluate its value for the cost. Exactly because of this 
reason, the same research group recently failed to conduct a randomized clinical trial 
comparing inpatient and outpatient psychotherapy for cluster C PD. To overcome the 
problem of selection bias, we controlled for initial differences in patient characteristics with 
the propensity score method.32  
It can be concluded from our model-based analysis that outpatient psychotherapy and 
day hospital psychotherapy are the optimal treatments for patients with cluster B PD in terms 
of cost per recovered patient-year and cost per QALY. The ultimate selection depends on 
what cost-effectiveness threshold is considered acceptable and what perspective is adopted. 
The decision whether or not to adopt a treatment strategy is inevitably made in a context of 
uncertainty surrounding the cost-effectiveness of these strategies, and therefore there is a 
possibility of making a wrong decision on a patient level. Future work should include a so-
called value of information analysis which evaluates the extent to which additional evidence 
might reduce the probability and the consequences (costs) of a wrong decision and 
compares that improvement with the cost of information.  
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Figures 
 
Figure 1. State transition diagram of the Markov model for psychotherapy 
 
 
 
Figure 2. Scatter plots showing the costs and health outcomes of the treatment 
strategies from 1000 Monte Carlo simulations. A, for recovered patient-years. B, for 
QALYs. 
 
 
Figure 3. Cost-effectiveness acceptability curves (CEAC) showing the probability of 
each modality being cost-effective at different values of the societal WTP. A, CEAC for 
recovered patient-year. B, CEAC for QALY. 
 
Figure 4. Cost-effectiveness acceptability frontiers (CEAF) showing the optimal 
modality for each value of the societal WTP. A, CEAF for recovered patient-year. B, 
CEAF for QALY. 
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